Chitosan Microspheres as Potential Vaccine Delivery Systems
Keywords:
Tetanus toxoid, Chitosan microspheres, Vaccine delivery system, Biodegradable polymersAbstract
The recent advances in controlled delivery systems for protein pharmaceuticals such as microspheres, liposomes, pumps and implants, have provided a new avenue for delivery of vaccine antigens. Adjuvants aimed at increasing the immunogenicity of recombinant antigens remain a focus in vaccine development worldwide, there is currently considerable care for the development of chitosan microspheres as controlled release of vaccines, since the major disadvantage of several currently available vaccines is the need for repeated administration. Microspheres prepared from the biodegradable and biocompatible polymers, chitosan have been shown to be effective adjuvants for a number of antigens. This review mainly focuses on chitosan microspheres adjuvant as vaccine delivery systems by summarizing our and other research groups’ investigation on properties of microspheres formulation encapsulating several kinds of antigens. The results indicate that compared with commonly used PLA and PLGA, chitosan biomaterial has several potentials in vaccine delivery systems. Chitosan microspheres can control the rate of release of entrapped antigens and therefore, offer generation adjuvant to replace or complement existing aluminium salts for vaccine potential. The review mainly aims to promote the investigation of chitosan microspheres adjuvant for antigens for world wide researcher.
References
Plotkin SL, Plotkin SA, in: Plotkin SA,
Mortimer EA Jr. (Eds). A short history of
vaccination and vaccines, Saunders,
Philadelphia, PA, 1988, 1-7.
Shari Lofthouse. Immunological aspects of
controlled antigen delivery. Adv Drug Deli
Rev 2002; 54:863-870.
Men Y, Thomasin C, Merkle HP, Gander B,
Corradin G. A Single administration of
tetanus toxin in biodegradable microspheres
elicits T cell and antibody responses similar
or superior to those obtained with aluminium
hydroxide. Vaccine 1995; 13:683-689.
Warren HS, Vogel FR, Chedid LA. Current
status of immunological adjuvants. Ann Rev
Immunol 1986;4: 369-376.
Kohn J, Niemi SM, Albert EC, Murphy JC,
Langer RS, Fox JG. Single-step
immunization using a controlled release,
biodegradable polymer with sustained
adjuvant activity. J Immunol Methods 1986;
: 31- 37.
Physician’s Desk Reference, 46th ed, Medical
Economics Data. 1992; 1544-1546.
Bittle JL, Murphy FL. Vaccine Biotechnol.
; 33: 313.
Allison AC, Byars NE. Immunological
adjuvants: desirable properties and side
effects. Molec Immunol 1991; 28: 279-283.
Zhao Z, Leong KW. Controlled delivery of
antigens and adjuvants in vaccine
development. J Pharm Sci 1996; 85 (12):
-1270.
Nellore RV, Pande PG, Young D, Bhagat
HR. Evaluation of biodegradable
microspheres as vaccine adjuvant for
Hepatitis B surface antigen. J Parenteral Sci
Tech 1992; 46: 176-180.
Yamaguchi K, Anderson JM. In vivo
biocompatibility studies of medisorb 65/35
D.L-lactide / glycolide copolymer
microspheres. J Control Release 1993; 24: 81-
Aguado MT, Lambert PH. Controlled release
vaccines biodegradable polylactidepolyglycolide (PL / PG) microspheres as
antigen vehicles. Immunobiol 1992;184: 113-
Esparza I, Kissel T. Parameters affecting the
immunogenicity of microencapsulated tetanus
toxoid. Vaccine 1992; 10: 714-720.
Raghuvanshi RS, Singh M, Talwar GP.
Biodegradable delivery system for single step
immunization with tetanus toxoid. Int J
Pharm 1993; 93: R1-R5.
Alonso MJ, Cohen S, Park TG, Gupta RK,
Siber GR, Langer R. Determinants of release
rate of tetanus vaccine from polyester
microspheres. Pharm.Res 1993;10: 945-953.
Alonso MJ, Gupta RK, Min C, Siber GR,
Langer R. Biodegradable microspheres as
controlled-release tetanus toxoid delivery
systems. Vaccine 1994; 12: 299-306.
Change AC, Gupta RK. Stabilization of
tetanus toxoid in poly (D,L,lactide-coglycolic acid) microspheres for the controlled
release of antigen. J Pharm Sci 1996; 85: 129-
Langer R. New methods of drug delivery.
Science 1990; 249: 1527-1533.
Tice TR, Mason DW, Ghley RM. Clinical use
and future of parenteral microspheres delivery
systems, in: F.Prescot, W.S.Nimmo (Eds.),
Drug Delivery and its Therapeutic
Applications, Wiley, London, 1989, Chapter
Wise DL, Fellman TD, Sanderson JE,
Wentworth RL. Lactide / glycolide polymers
used in as surgical suture material, raw
material for osteosynthesis and in sustained
release forms of drugs, in:G.Gregoriadis
(Ed.), Drug Carriers in Medicine, Academic
Press, London. 1979; 237.
Singh M, Li XM, Wang HY, McGee JP,
Zamb T, Koff W, Wang CY, O’Hagan DT.
Immunogenecity and protection in small
animal models with controlled release tetanus
toxoid microparticles as a single-dose
vaccine. Infect Immun 1997;65: 1716-1721.
Illum L. Chitosan and its use as a
pharmaceutical excipient. Pharm Res 1998;
:1326-1331.
Felt O, Buri P, Gurny R. Chitosan: a unique
polysaccharide for drug delivery. Drug Dev
Ind Pharm 1998; 24:979-993.
Joane RJ, Frier M, Perkins AC, Jones NS,
Davis SS, Illum L. Evaluation of the
clearance characteristics of bioadhesive
systems in humans. Int J Pharm 1999;
:55-65.
Vander Lubben LM, Verhoef JC, Borchard G,
Junginger HE. Chitosans for mucosal
vaccination. Adv Drug Deliv Rev
;52:139-144.
Derek T, O’Hagan DT, Rino Rappuoli. Novel
approaches to vaccine delivery.
Pharmaceutical Research 2004; 21(9): 1519-
Valiante NM, O’Hagan DT, Ulmer J. Innate
immunity and biodefense vaccines. Cell
Microbiol 2003; 5:755-760.
Artursson P, Lindmark T, Davis SS, Illum L.
Effect of chitosan on the permeability of
monolayers of intestinal epithelial cells
(Caco-2). Pharm Res 1994; 11:1358–1361.
Borchard G, Luessen HL, De Boer AG,
Verhoef JC, Lehr CM, Junginger HE. The
poteltial of mucoadhesive polymers in
enhancing intestinal peptide drus absorption.
III: Effect of chitosan glutamate and
carbomer on epithelial tight junctions in vitro.
J Control Release 1996; 39:131–138.
Dodane V, Khan MA, Merwin JR. Effect of
chitosan on epithelial permeability and
structure. Int J Pharm 1999; 182:21–32.
Schipper NG, Varum KM, Artursson P.
Chitosans as absorption enhancers for poorly
absorbable drugs. 1: Influence of molecular
weight and degree of acetylation on drug
transport across human intestinal epithelial
(Caco-2) cells. Pharm Res 1996; 13:1686–
Luessen HL, de Leeuw BJ, Langemeyer MW,
de Boer AB, Verhoef JC, Junginger HE.
Mucoadhesive polymers in peroral peptide
drug delivery. VI. Carbomer and chitosan
improve the intestinal absorption of the
peptide drug buserelin in vivo. Pharm Res
; 13:1668–1672.
Jabbal-Gill I, Fisher AN, Rappuoli R, Davis
SS, Illum L. Stimulation of mucosal and
systemic antibody responses against
Bordetella pertussis filamentous
haemagglutinin and recombinant pertussis
toxin after nasal administration with chitosan
in mice. Vaccine 1998; 16:2039–2046.
McNeela EA, O'Connor D, Jabbal-Gill I,
Illum L, Davis SS, Pizza M, et al. A mucosal
vaccine against diphtheria: formulation of
cross reacting material (CRM (197)) of
diphtheria toxin with chitosan enhances local
and systemic antibody and Th2 responses
following nasal delivery. Vaccine 2000;
:1188–1198.
Xie Y, Zhou NJ, Gong YF, Zhou XJ, Chen J,
Hu SJ, et al. Th immune response induced by
H. pylori vaccine with chitosan as adjuvant
and its relation to immune protection. World J
Gastroenterol 2007; 13:1547–1553.
Seferian PG, Martinez ML. Immune
stimulating activity of two new chitosan
containing adjuvant formulations. Vaccine
; 19:661–668.
Soane RJ, Hinchcliffe M, Davis SS, Illum L.
Clearance characteristics of chitosan based
formulations in the sheep nasal cavity. Int J
Pharm 2001;217:183–191.
Desai MP, Labhasetwar V, Walter E, Levy
RJ, Amidon GL. The mechanism of uptake of
biodegradable microparticles in Caco-2 cells
is size dependent. Pharm Res 1997; 14:1568–
Eldridge JH, Staas JK, Meulbroek JA, Tice
TR, Gilley RM. Biodegradable and
biocompatible poly(DL-lactide-co-glycolide)
microspheres as an adjuvant for
staphylococcal enterotoxin B toxoid which
enhances the level of toxin-neutralizing
antibodies. Infect Immun 1991; 59:2978–
O'Hagan DT, Jeffery H, Davis SS. Long-term
antibody responses in mice following
subcutaneous immunization with ovalbumin
entrapped in biodegradable microparticles.
Vaccine 1993a; 11:965–969.
Pereswetoff-Morath L. Microspheres as nasal
drug delivery systems. Adv Drug Deliv Rev
;29:185–194.
Chowdary KP, Rao YS. Mucoadhesive
microspheres for controlled drug delivery.
Biol Pharm Bull 2004;27:1717–1724.
Tian J, Yu J, Sun X. Chitosan microspheres
as candidate plasmid vaccine carrier for oral
immunisation of Japanese flounder
(Paralichthys olivaceus). Vet Immunol
Immunopathol 2008; 126:220–229.
Ahire VJ, Sawant KK, Doshi JB, Ravetkar
SD. Chitosan microparticles as oral delivery
system for tetanus toxoid. Drug Dev Ind
Pharm 2007;33:1112–1124.
Takahiro Nagamoto, Yoshiyuki Hattori, Kozo
Takayama, Yoshie Maitani. Novel chitosan
particles and chitosan-coated emulsions
inducing immune response via intranasal
vaccine delivery. Pharmacological Research,
(4), 671-674 (2004).
Arthanari Saravanakumar, Nachipalayam
Muthusamy Ramaswamy. Formulation and
in-vitro evaluation of tetanus toxoid loaded
chitosan microspheres. J of Pharm Research
; 2(5): 893-896.
